Topical Drugs CDMO Market Analysis

Topical Drugs CDMO Market Analysis

To get key market trends

  Download Free Sample

Based on product type, the market is segmented into semi-solid formulations, liquid formulations, transdermal products, and solid formulations. The semi-solid segment accounted for USD 27.3 billion in 2023. The semi-solid formulations segment is further sub-segmented into creams, ointments, gels, and other semi-solid formulations.
 

• Semi-solid formulations have gained prominence due to their widespread use in treating various skin conditions. These formulations effectively deliver active pharmaceutical ingredients (APIs) directly to affected areas, providing targeted treatment with minimal systemic absorption, making them ideal for dermatological applications.
   
• The versatility and ease of application of semi-solid formulations have made them the preferred choice for both prescription and over the counter drugs. They are commonly used to treat conditions such as acne, eczema, psoriasis, and fungal infections, which are highly prevalent globally.
   
• This has led to an increasing demand for semi-solid topical treatments, prompting pharmaceutical companies to expand their product portfolios in this segment.
   

Based on therapeutic areas, the topical drugs CDMO market is classified into dermatology, pain management, wound care, ophthalmology, and other therapeutic areas. The dermatology segment dominated the market with 34.5% of market share in 2023.
 

• The dermatology segment's prominence was due to the high prevalence of skin disorders and the rising demand for effective topical treatments.
   
• Conditions such as acne, psoriasis, eczema, and skin infections affect millions globally, driving pharmaceutical companies to develop innovative topical formulations to address these issues. Topical medications are often the first line of treatment in dermatology, as they allow for localized application, delivering active ingredients directly to affected areas with minimal systemic absorption.
   
• Furthermore, as pharmaceutical companies expand their dermatology pipelines, many are turning to CDMOs for specialized expertise in developing and manufacturing topical formulations, such as creams, gels, ointments, and lotions.
   

Based on service type, the topical drugs CDMO market is categorized into contract manufacturing and contract development. The contract manufacturing segment held the highest market share and is expected to grow at a 10.2% CAGR over the analysis period.
 

• Contract manufacturing has emerged as the dominant segment due to its ability to offer cost-effective, scalable, and efficient production solutions for pharmaceutical companies.
   
• Furthermore, the rise in demand for topical drugs, driven by the increasing prevalence of skin conditions such as acne, psoriasis, and dermatitis, has further fueled the need for contract manufacturing services.
   
• CDMOs offer specialized expertise in producing semi-solid and liquid formulations, which are the most common forms of topical medications. Their capability to ensure regulatory compliance, high-quality standards, and flexibility in production makes them an essential partner in the supply chain.
   

Based on end use, the topical drugs CDMO market is divided into pharmaceutical companies, biotechnology companies, and other end-users. The pharmaceutical companies' segment is projected to reach USD 67.1 billion by 2032.
 

• Pharmaceutical companies' dominance was attributed to their increasing reliance on outsourcing for drug development and manufacturing.
   
• As the demand for topical treatments grows, driven by the rising incidence of dermatological conditions, pharmaceutical companies are expanding their topical drug pipelines.
   
• This has led to greater collaboration with CDMOs, which provide the necessary expertise and infrastructure for efficient production, ensuring companies can meet market demands while maintaining quality standards.
   
• Outsourcing to CDMOs enables pharmaceutical companies to reduce costs and mitigate the risks associated with in-house manufacturing, such as regulatory compliance, production scalability, and technological advancements. By partnering with CDMOs, they can focus on their core competencies, such as research and marketing, while leveraging the manufacturing capabilities of specialized organizations.
   

U.S. topical drugs CDMO market is expected to grow at 10.1% CAGR, to reach USD 35 billion by 2032.
 

• The presence of leading CDMOs in the U.S. enhances the country's ability to produce high-quality topical products. These CDMOs frequently collaborate with pharmaceutical companies to streamline the development process, ensuring efficient time-to-market for new formulations.
   
• For example, in January 2023, Swiss American CDMO partnered with LiquiGlide, the developers of the EveryDrop dispensing platform. This collaboration expanded Swiss American's offerings by incorporating LiquiGlide's innovative technology into the global skincare market.
   
• This partnership is expected to significantly boost the market in the U.S. by enhancing product efficiency and reducing waste, catering to the growing demand for sustainable and effective skincare solutions.
   
• Furthermore, with growing healthcare awareness, patients are increasingly seeking non-invasive treatments to manage their conditions. This shift has spurred demand for topical medications, which offer effective relief without the complications associated with oral drugs.
   
• Consequently, this trend is fueling growth in the U.S. market, as manufacturers expand their development and manufacturing capabilities to meet the increasing demand.
   

The Germany topical drugs CDMO market is experiencing robust growth in the Europe market.
 

• Germany's stringent regulatory standards push manufacturers to work with CDMOs that can ensure high-quality production while meeting compliance requirements for Good Manufacturing Practices (GMP), making local CDMOs preferred partners.
   
• Furthermore, Germany is a leading pharmaceutical market in Europe with high export potential. CDMOs in Germany benefit from partnerships with large pharmaceutical companies looking to outsource production, especially for topical products aimed at both domestic and international markets, thereby contributing to the growth of the market.
   
• Additionally, there is a rising demand for customized topical treatments for niche markets, such as dermatology and cosmetics, where patients seek tailored formulations. This trend has pushed CDMOs to offer flexible, small batch manufacturing capabilities, adding to market growth.
   

The Asia Pacific topical drugs CDMO market is witnessing substantial growth of 10.8% during the analysis period.
 

• Chinese consumers show high demand for beauty and skin-care products, particularly in urban areas. The increased focus on aesthetic dermatology propels the need for innovative topical formulations that CDMOs can produce.
   
• Moreover, international pharmaceutical companies are increasingly partnering with Chinese CDMOs due to the large local market potential and quality manufacturing capabilities, which supports CDMO expansion, contributing to the market growth.
   

Brazil topical drugs CDMO market is experiencing robust growth in the Latin America market.
 

• Brazil has a high incidence of dermatological conditions like acne, psoriasis, and fungal infections due to its tropical climate and high humidity. The demand for topical drugs is increasing as the population seeks effective treatment options for these conditions; therefore, these factors are expected to drive the growth of the market.
   
• Additionally, the Brazilian government has implemented policies to encourage the growth of the pharmaceutical sector, including tax incentives, regulatory support, and investment incentives for manufacturing facilities, including CDMOs.
   

Saudi Arabia topical drugs CDMO market is witnessing substantial growth during the analysis period.
 

• Saudi Arabia is investing significantly in the pharmaceutical sector as part of its National Industrial Development and Logistics Program (NIDLP). This program emphasizes local production, creating opportunities for CDMOs to partner with global companies and establish local manufacturing facilities for topical drug formulations.
   
• Moreover, the Saudi Food and Drug Authority (SFDA) has streamlined regulations to promote local manufacturing with a focus on expedited approval processes and incentives for locally manufactured products. Therefore, the CDMOs specializing in topical drugs benefit from smoother regulatory pathways, encouraging faster production and market entry, which further propels the market growth.